. 2017 Feb 28;49(1):62–67. doi: 10.3947/ic.2017.49.1.62

Table 1. Comparison of the susceptibility rates for revised and previous clinical and laboratory standards institute (CLSI) for broad-spectrum cephalosporins for Enterobacteriaceae ^a .

Drug	MIC Interpretive Criteria (µg/mL)				Zone Diameter Interpretive Criteria (mm)
Drug	S	SDD	I	R	S	SDD	I	R
Cefotaxime
Previous	≤8	-	16–32	≥64	≥23	-	15–22	≤14
Revised	≤1	-	2	≥4	≥26	-	23–25	≤22
Ceftazidime
Previous	≤8	-	16–32	≥64	≥18	-	15–17	≤14
Revised	≤4	-	8	≥16	≥21	-	18–20	≤17
Cefepime
Previous	≤8	-	16	≥32	≥18	-	15–17	≤14
Revised	≤2	4–8	-	≥16	≥25	19–24	-	≤18

MIC, minimum inhibitory concentration; S, susceptible; SDD, susceptible-dose dependent; I, intermediate; R, resistant.

^aCLSI revised interpretative criteria (breakpoints) for ceftriaxone and ceftazidime in 2011 [1] and interpretative criteria (breakpoints) for cefepime in 2014 [2].

Table 1. Comparison of the susceptibility rates for revised and previous clinical and laboratory standards institute (CLSI) for broad-spectrum cephalosporins for Enterobacteriaceae a .

Table 1. Comparison of the susceptibility rates for revised and previous clinical and laboratory standards institute (CLSI) for broad-spectrum cephalosporins for Enterobacteriaceae ^a .